Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets...

Published on 13 Dec 2024 on Benzinga · via Yahoo Finance

On Thursday, Editas Medicine Inc. (NASDAQ:EDIT) announced a strategic realignment to focus on in...

Read the rest of the article

Start tracking your investments with Statfolio

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts t...

Zacks · via Yahoo Finance 16 Dec 2024

Big changes, including major layoffs, are coming at Editas Medicine Inc. as the biotech lays off ...

The Business Journals 13 Dec 2024

On Thursday, Editas Medicine Inc. (NASDAQ:EDIT) announced a strategic realignment to focus on in...

Benzinga · via Yahoo Finance 13 Dec 2024

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge...

Insider Monkey · via Yahoo Finance 31 Oct 2024

Overview of Recent Transaction by State Street Corp On September 30, 2024, State Street Corp exec...

GuruFocus.com · via Yahoo Finance 17 Oct 2024

We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this...

Insider Monkey · via Yahoo Finance 19 Jun 2024

We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we a...

Insider Monkey · via Yahoo Finance 19 Jun 2024

Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 ...

GuruFocus.com via Yahoo Finance 23 May 2024

On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,00...

GuruFocus.com via Yahoo Finance 16 May 2024

Editas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not ...

Simply Wall St. via Yahoo Finance 9 May 2024